Compare · ARGX vs VOR
ARGX vs VOR
Side-by-side comparison of argenx SE (ARGX) and Vor Biopharma Inc. (VOR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ARGX and VOR operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- ARGX is the larger of the two at $55.32B, about 77.6x VOR ($713.1M).
- Over the past year, ARGX is up 50.4% and VOR is up 197.7% - VOR leads by 147.3 points.
- ARGX has been more active in the news (5 items in the past 4 weeks vs 4 for VOR).
- ARGX has more recent analyst coverage (25 ratings vs 16 for VOR).
- Company
- argenx SE
- Vor Biopharma Inc.
- Price
- $877.85-1.56%
- $13.29+0.95%
- Market cap
- $55.32B
- $713.1M
- 1M return
- +11.51%
- -17.37%
- 1Y return
- +50.42%
- +197.69%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2017
- 2021
- News (4w)
- 5
- 4
- Recent ratings
- 25
- 16
argenx SE
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.Ã.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
Vor Biopharma Inc.
Vor Biopharma, Inc., early-stage cell therapy company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in preclinical development to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML cancer cells. Vor Biopharma, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Latest ARGX
- SEC Form 6-K filed by argenx SE
- argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren's Disease at EULAR 2026
- argenx to Host Myositis R&D Webinar on June 23, 2026
- argenx to Present at Upcoming Investor Conferences
- The Biology Came First.
- SEC Form 6-K filed by argenx SE
- argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG
- SEC Form 6-K filed by argenx SE
- argenx Reports First Quarter 2026 Financial Results and Provides Business Update
- argenx to Present at BofA Securities 2026 Health Care Conference
Latest VOR
- Telitacicept Receives NMPA Approval for the Treatment of Sjögren's Disease in China
- Telitacicept Receives NMPA Conditional Approval for the Treatment of IgA Nephropathy in China
- Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Vor Bio to Participate in the 2026 Jefferies Global Healthcare Conference
- Amendment: SEC Form SCHEDULE 13G/A filed by Vor Biopharma Inc.
- Vor Bio Announces Publication of Interim Analysis of TELIGAN, a China Phase 3 Trial of Telitacicept in IgA Nephropathy, in The New England Journal of Medicine
- SEC Form 10-Q filed by Vor Biopharma Inc.
- Vor Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update
- SEC Form EFFECT filed by Vor Biopharma Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Vor Biopharma Inc.